Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.08
ESRX's Cash to Debt is ranked lower than
85% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.70 vs. ESRX: 0.08 )
Ranked among companies with meaningful Cash to Debt only.
ESRX' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.26 Max: No Debt
Current: 0.08
Equity to Asset 0.30
ESRX's Equity to Asset is ranked lower than
56% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.38 vs. ESRX: 0.30 )
Ranked among companies with meaningful Equity to Asset only.
ESRX' s Equity to Asset Range Over the Past 10 Years
Min: 0.11  Med: 0.32 Max: 0.58
Current: 0.3
0.11
0.58
Interest Coverage 8.69
ESRX's Interest Coverage is ranked lower than
60% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 11.38 vs. ESRX: 8.69 )
Ranked among companies with meaningful Interest Coverage only.
ESRX' s Interest Coverage Range Over the Past 10 Years
Min: 4.51  Med: 8.18 Max: 16.5
Current: 8.69
4.51
16.5
F-Score: 8
Z-Score: 3.12
M-Score: -2.59
WACC vs ROIC
6.56%
9.90%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 4.51
ESRX's Operating margin (%) is ranked higher than
56% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 4.35 vs. ESRX: 4.51 )
Ranked among companies with meaningful Operating margin (%) only.
ESRX' s Operating margin (%) Range Over the Past 10 Years
Min: 2.98  Med: 4.65 Max: 6.06
Current: 4.51
2.98
6.06
Net-margin (%) 2.64
ESRX's Net-margin (%) is ranked higher than
58% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.76 vs. ESRX: 2.64 )
Ranked among companies with meaningful Net-margin (%) only.
ESRX' s Net-margin (%) Range Over the Past 10 Years
Min: 1.4  Med: 2.67 Max: 3.53
Current: 2.64
1.4
3.53
ROE (%) 16.77
ESRX's ROE (%) is ranked higher than
72% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 10.49 vs. ESRX: 16.77 )
Ranked among companies with meaningful ROE (%) only.
ESRX' s ROE (%) Range Over the Past 10 Years
Min: 8.16  Med: 34.38 Max: 87.47
Current: 16.77
8.16
87.47
ROA (%) 5.18
ESRX's ROA (%) is ranked higher than
69% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.50 vs. ESRX: 5.18 )
Ranked among companies with meaningful ROA (%) only.
ESRX' s ROA (%) Range Over the Past 10 Years
Min: 3.3  Med: 9.22 Max: 14.42
Current: 5.18
3.3
14.42
ROC (Joel Greenblatt) (%) 351.61
ESRX's ROC (Joel Greenblatt) (%) is ranked higher than
77% of the 22 Companies
in the Global Health Care Plans industry.

( Industry Median: 96.12 vs. ESRX: 351.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ESRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 220.38  Med: 464.57 Max: 589.99
Current: 351.61
220.38
589.99
Revenue Growth (3Y)(%) 5.30
ESRX's Revenue Growth (3Y)(%) is ranked lower than
67% of the 24 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.70 vs. ESRX: 5.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ESRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 5.3  Med: 22 Max: 69.7
Current: 5.3
5.3
69.7
EBITDA Growth (3Y)(%) 15.50
ESRX's EBITDA Growth (3Y)(%) is ranked higher than
71% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.50 vs. ESRX: 15.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ESRX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 3.2  Med: 22.8 Max: 91
Current: 15.5
3.2
91
EPS Growth (3Y)(%) 25.50
ESRX's EPS Growth (3Y)(%) is ranked higher than
65% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.70 vs. ESRX: 25.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ESRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 1.4  Med: 25.5 Max: 74.6
Current: 25.5
1.4
74.6
» ESRX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ESRX Guru Trades in Q3 2015

Steven Cohen 286,700 sh (+428.97%)
Joel Greenblatt 146,565 sh (+136.07%)
Paul Tudor Jones 17,374 sh (+45.38%)
Ray Dalio 103,662 sh (+21.01%)
Pioneer Investments 3,380,986 sh (+2.93%)
Dodge & Cox 28,405,375 sh (+1.69%)
Jeff Auxier 73,997 sh (unchged)
First Eagle Investment 1,168 sh (unchged)
Ruane Cunniff 4,905 sh (unchged)
First Pacific Advisors 84,100 sh (unchged)
Keeley Asset Management Corp 27,948 sh (unchged)
Vanguard Health Care Fund Sold Out
Glenn Greenberg Sold Out
Mario Gabelli 116,759 sh (-1.77%)
Charles Brandes 2,116,586 sh (-1.94%)
Scott Black 111,817 sh (-2.19%)
Manning & Napier Advisors, Inc 4,555,830 sh (-3.84%)
Wallace Weitz 1,066,089 sh (-5.45%)
Diamond Hill Capital 1,475,679 sh (-5.73%)
HOTCHKIS & WILEY 1,762,200 sh (-6.91%)
David Rolfe 5,746,965 sh (-12.14%)
Ken Fisher 459,838 sh (-13.80%)
Chris Davis 9,164,920 sh (-29.44%)
Jeremy Grantham 4,591,655 sh (-56.90%)
First Pacific Advisors 1,551,395 sh (-66.69%)
Steven Romick 1,329,620 sh (-68.60%)
» More
Q4 2015

ESRX Guru Trades in Q4 2015

Robert Olstein 49,000 sh (New)
Steve Mandel 3,193,180 sh (New)
Joel Greenblatt 357,260 sh (+143.76%)
Ken Fisher 464,733 sh (+1.06%)
First Eagle Investment 1,168 sh (unchged)
Jeff Auxier 73,997 sh (unchged)
First Pacific Advisors 84,100 sh (unchged)
Samuel Isaly 378,000 sh (unchged)
Steven Romick Sold Out
Steven Cohen Sold Out
Diamond Hill Capital 1,475,490 sh (-0.01%)
Wallace Weitz 1,058,456 sh (-0.72%)
Mario Gabelli 115,034 sh (-1.48%)
Charles Brandes 2,041,802 sh (-3.53%)
HOTCHKIS & WILEY 1,590,250 sh (-9.76%)
Ray Dalio 93,162 sh (-10.13%)
Dodge & Cox 25,520,318 sh (-10.16%)
Ruane Cunniff 4,379 sh (-10.72%)
David Rolfe 5,120,114 sh (-10.91%)
Manning & Napier Advisors, Inc 3,437,836 sh (-24.54%)
Jeremy Grantham 3,203,292 sh (-30.24%)
Paul Tudor Jones 11,504 sh (-33.79%)
Chris Davis 5,531,779 sh (-39.64%)
Pioneer Investments 1,954,238 sh (-42.20%)
Keeley Asset Management Corp 15,820 sh (-43.39%)
Scott Black 24,202 sh (-78.36%)
First Pacific Advisors 56,680 sh (-96.35%)
» More
Q1 2016

ESRX Guru Trades in Q1 2016

George Soros 3,000 sh (New)
Leucadia National 3,800 sh (New)
Jim Simons 628,139 sh (New)
David Dreman 15,504 sh (New)
Barrow, Hanley, Mewhinney & Strauss 9,772,328 sh (New)
Paul Tudor Jones 57,136 sh (+396.66%)
Ray Dalio 394,218 sh (+323.15%)
Joel Greenblatt 1,158,428 sh (+224.25%)
Robert Olstein 131,100 sh (+167.55%)
Manning & Napier Advisors, Inc 3,655,550 sh (+6.33%)
Charles Brandes 2,168,388 sh (+6.20%)
Jeff Auxier 74,035 sh (+0.05%)
First Eagle Investment 1,168 sh (unchged)
Samuel Isaly 378,000 sh (unchged)
Scott Black Sold Out
Steve Mandel Sold Out
Ruane Cunniff Sold Out
First Pacific Advisors Sold Out
Wallace Weitz 1,057,939 sh (-0.05%)
HOTCHKIS & WILEY 1,554,950 sh (-2.22%)
Mario Gabelli 108,748 sh (-5.46%)
Chris Davis 5,142,979 sh (-7.03%)
Dodge & Cox 22,069,813 sh (-13.52%)
Ken Fisher 375,624 sh (-19.17%)
David Rolfe 3,987,074 sh (-22.13%)
Keeley Asset Management Corp 9,629 sh (-39.13%)
Jeremy Grantham 1,624,557 sh (-49.28%)
Diamond Hill Capital 3,394 sh (-99.77%)
Pioneer Investments 3,190 sh (-99.84%)
» More
Q2 2016

ESRX Guru Trades in Q2 2016

Arnold Van Den Berg 97,615 sh (New)
Larry Robbins 72,122 sh (New)
Paul Tudor Jones 526,800 sh (+822.01%)
David Dreman 27,122 sh (+74.94%)
Barrow, Hanley, Mewhinney & Strauss 14,646,371 sh (+49.88%)
First Eagle Investment 1,168 sh (unchged)
Robert Olstein 131,100 sh (unchged)
Jeff Auxier 74,035 sh (unchged)
Jim Simons Sold Out
George Soros Sold Out
Leucadia National Sold Out
Keeley Asset Management Corp Sold Out
Pioneer Investments Sold Out
Wallace Weitz 1,046,771 sh (-1.06%)
Dodge & Cox 21,691,413 sh (-1.71%)
Charles Brandes 2,126,580 sh (-1.93%)
Manning & Napier Advisors, Inc 3,569,730 sh (-2.35%)
Chris Davis 4,955,717 sh (-3.64%)
Ken Fisher 352,068 sh (-6.27%)
Mario Gabelli 97,743 sh (-10.12%)
Joel Greenblatt 962,979 sh (-16.87%)
Diamond Hill Capital 2,785 sh (-17.94%)
David Rolfe 3,251,358 sh (-18.45%)
Ray Dalio 311,618 sh (-20.95%)
Jeremy Grantham 1,127,881 sh (-30.57%)
HOTCHKIS & WILEY 775,261 sh (-50.14%)
Samuel Isaly 318,800 sh (-15.66%)
» More
» Details

Insider Trades

Latest Guru Trades with ESRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Plans » Health Care Plans
Compare:NYSE:AET, NYSE:CI, NYSE:HUM, NYSE:CNC, NYSE:ANTX, NYSE:HNT, NYSE:WCG, NYSE:MOH, NAS:MGLN, NYSE:UAM, NAS:HIIQ, NAS:CNXR, OTCPK:OPRX, OTCPK:WCUI, NYSE:CVS, NYSE:UNH » details
Traded in other countries:ESRX34.Brazil, 4XS.Germany, ESRX.Mexico, ESRX.Switzerland, 0R0W.UK,
Express Scripts Holding Co offers healthcare management & administration services such as managed care organizations, health insurers, workers' compensation plans & government health programs.

Express Scripts Holding Co was incorporated in the State of Delaware on July 15, 2011 as Aristotle Holding, Inc. It operates as a Pharmacy benefit management in North America. It includes HMOs, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans and government health programs. It helps health benefit providers address access and affordability concerns resulting from rising drug costs while helping to improve healthcare outcomes. It works with clients, manufacturers, pharmacists and physicians to increase efficiency in the drug distribution chain, to manage costs in the pharmacy benefit and to improve members' health outcomes and satisfaction. The Company supports healthier outcomes by applying science to health decisions. It offers solutions in four areas namely benefit choices, drug choices, pharmacy choices and health choices. Health Decision ScienceSM is the Company's approach to understand and improve the decisions that impact clinical and financial outcomes and applies principles and knowledge from three disciplines: behavioral sciences, clinical specialization and actionable data. These disciplines form a powerful combination that seeks to increase the likelihood of healthier decisions and healthier outcomes. Consumerology(r), or the application of the behavioral sciences to healthcare, optimizes decision mechanisms and helps make decisions easier. Therapeutic Resource CentersSM gives patients access to specialist pharmacists and nurses to close gaps in care. It has organized its operations into two business segments based on products and services offered PBM and Business Operations. The Company's PBM segment consists services such as the retail network pharmacy administration, home delivery pharmacy services, benefit design consultation, drug utilization review, drug formulary management, clinical solutions to improve health outcomes, such as adherence, case coordination and personalized medicine, flexible array of Medicare Part D, Medicaid and Health Insurance Marketplace offerings to support clients' benefits, specialty pharmacy, including the distribution of fertility pharmaceuticals requiring special handling or packaging, administration of a group purchasing organization and consumer health and drug information. The Business Operations segment consists of distribution of pharmaceuticals and medical supplies to providers and clinics and scientific evidence to guide the safe, effective and affordable use of medicines. The Company is subject to federal and state laws and regulations.

Guru Investment Theses on Express Scripts Holding Co

David Rolfe Comments on Express Scripts - Jul 13, 2016

Express Scripts (NASDAQ:ESRX) was a top contributor during the quarter. The stock recovered some of the poor performance from the first quarter after Anthem management noted that, despite filing a lawsuit over Express Scripts’s pricing, they believed any ruling on the lawsuit would take several years and were still open to negotiations. Express Scripts is the sole, independent pharmacy benefits manager (PBM), which we think is key for maintaining their alignment with customers. We continue to expect Express Scripts to drive mid-to-high single-digit EBITDA growth using its scale to negotiate better pricing with drug manufacturers and service providers, while increasing patient adherence. We think earnings per share can continue to grow at a double-digit rate as shares are repurchased at what, in our view, are attractive valuations. That said, as shares rallied from their previous lows, we reduced the stock's weighting to better reflect the risk/reward of Express Scripts’s growth and valuation.

From David Rolfe (Trades, Portfolio)'s second quarter 2016 Wedgewood Partners Client Letter.

Check out David Rolfe latest stock trades

Brandes Investments Comments on Express Scripts - Jun 15, 2016

Express Scripts (NASDAQ:ESRX) declined 20% during the quarter due to a dispute with its largest client, health insurer Anthem (which accounts for 15%-20% of Express Scripts’ sales), as Anthem believes that Express Scripts needs to pass on larger drug cost savings to its customers. Under the existing contract, Anthem is entitled to a good-faith repricing of the contract terms, the deadline for which was December 15, 2015. As the deadline has passed and Express Scripts still has not provided Anthem with an offer that Anthem deems acceptable, Anthem has recently decided to take legal action against Express Scripts. Express Scripts’ CEO stated the company intends to resolve the dispute and keep Anthem as a customer.



We believe the market has over-reacted to the dispute as the current valuation prices in more than a complete loss of the Anthem contract. While there are multiple possibilities, we believe the most likely outcome is a renegotiation to extend the contract, likely at a lower margin but with increased volumes due to Anthem’s acquisition of Cigna. However there is a risk that Anthem switches to another vendor or brings the business in-house, although it lacks scale relative to peers. Given that the market seems to have priced in the worst-case outcome, we continue to believe that Express Scripts offers an attractive margin of safety.



From Brandes' Global Equity Fund first quarter 2016 commentary.



Check out Charles Brandes latest stock trades

Wallace Weitz Comments on Express Scripts - Apr 22, 2016

Express Scripts (NASDAQ:ESRX) is the largest stand-alone pharmacy benefits manager (PBM) in the United States, helping health benefit providers improve access to (and the affordability of) prescription drugs. Negotiations with Anthem, Express Scripts’ largest customer, hit an impasse early in the quarter. Anthem elected to bring the details of the disagreement public at a widely attended industry conference in January, providing the investment community a lens into how far the two companies were apart on the economics of their existing contract. Since then, Anthem has also filed a lawsuit against Express Scripts. While we hope a mutually agreeable solution will eventually be achieved, it remains possible (some believe likely) that Anthem will choose not to renew its contract with Express in 2019. We have run scenarios encompassing a range of different outcomes, and we believe Express Scripts’ shares are undervalued in all but the most dire. We continue to monitor contract-related developments and are otherwise heartened by improved execution across the other 84% of Express Scripts’ enterprise.

From Wallace Weitz (Trades, Portfolio)'s Weitz Value Fund 1st quarter 2016 commentary.

Check out Wallace Weitz latest stock trades

Dodge & Cox Comments on Express Scripts - Nov 19, 2015

Over the past decade, Express Scripts (NASDAQ:ESRX) has been a significant beneficiary of three industry trends: increased generic penetration, mail order pharmacy growth, and industry consolidation. The past round of mergers—CVS/Caremark, Express Scripts/Medco Health Solutions (Medco), and SXC Health Solutions/Catalyst Health—has created an oligopolistic market structure where the top three players now control over 65% of industry volumes.



Following its merger with Medco in 2012, Express Scripts became the largest PBM in the United States. The company now generates over $100 billion in annual revenue and manages 1.3 billion claims, or 30 percent of all U.S. prescription claims. Today, the company operates three vertically integrated businesses: a basic pharmacy benefit manager, a mail order pharmacy, and a specialty pharmacy. Express Scripts has achieved measurable growth by providing patients with generic drugs. With multiple equivalent treatments available, the company has used its buying power to save money for customers and generate profits; its mission is well aligned with customers looking to reduce health care and pharmacy cost trends. This strategy has boosted generic drug penetration to high levels.



The upcoming challenge for Express Scripts is in specialty drugs, which are used to treat chronic, complex diseases, including cancer, hepatitis, and multiple sclerosis. In the United States, this segment accounts for only 1% of volume, yet 25 to 30% of all drug spending. Biotech companies have maintained pricing power in this segment as disease complexity necessitates innovative and unique therapies. At over ten times the price of the average prescription, however, a need exists to manage the costs of these drugs, which we view as an attractive long-term growth opportunity. Express Scripts, with 30% market share in specialty drugs, is best positioned to help patients receive needed treatments cost effectively. Given the emergence of biosimilars and substitute treatments for older biotech drugs, Express Scripts’ strategy has the potential to influence prices in this segment.



During the second quarter, we increased the Fund’s position in Express Scripts after weighing the company’s fundamental outlook against its valuation. We believe Express Scripts’ strong business franchise, significant scale advantage, financial stability, growth opportunities, and reasonable valuation at 15.5 times forward earnings present an attractive investment opportunity. On June 30, Express Scripts was a 2.1% position in the Fund.





From Dodge & Cox Global Stock Fund second quarter 2015 commentary.



Check out Dodge & Cox latest stock trades

Top Ranked Articles about Express Scripts Holding Co

Arnold Van Den Berg Buys 6 New Stocks, Gets More Bullish on Oil Companies His firm expects $70 oil
During the second quarter, founder of Austin-based Century Management Arnold Van Den Berg (Trades, Portfolio) cut back on his sizable positioning in gold miners while increasing holdings in health care and oil. Read more...
Van Den Berg Made 6 New Buys in 2nd Quarter Most purchases were in health care, but largest was in mass media
Arnold Van Den Berg (Trades, Portfolio), who founded Century Management more than 40 years ago, invested in half a dozen new buys in the second quarter. Most of Van Den Berg’s new buys were in health care-related companies, but his largest was not. Read more...
David Rolfe Comments on Express Scripts Guru stock highlight
Express Scripts (NASDAQ:ESRX) was a top contributor during the quarter. The stock recovered some of the poor performance from the first quarter after Anthem management noted that, despite filing a lawsuit over Express Scripts’s pricing, they believed any ruling on the lawsuit would take several years and were still open to negotiations. Express Scripts is the sole, independent pharmacy benefits manager (PBM), which we think is key for maintaining their alignment with customers. We continue to expect Express Scripts to drive mid-to-high single-digit EBITDA growth using its scale to negotiate better pricing with drug manufacturers and service providers, while increasing patient adherence. We think earnings per share can continue to grow at a double-digit rate as shares are repurchased at what, in our view, are attractive valuations. That said, as shares rallied from their previous lows, we reduced the stock's weighting to better reflect the risk/reward of Express Scripts’s growth and valuation. Read more...
Brandes Investments Comments on Express Scripts Guru stock highlight
Express Scripts (NASDAQ:ESRX) declined 20% during the quarter due to a dispute with its largest client, health insurer Anthem (which accounts for 15%-20% of Express Scripts’ sales), as Anthem believes that Express Scripts needs to pass on larger drug cost savings to its customers. Under the existing contract, Anthem is entitled to a good-faith repricing of the contract terms, the deadline for which was December 15, 2015. As the deadline has passed and Express Scripts still has not provided Anthem with an offer that Anthem deems acceptable, Anthem has recently decided to take legal action against Express Scripts. Express Scripts’ CEO stated the company intends to resolve the dispute and keep Anthem as a customer. Read more...
Barrow Hanley Mewhinney & Strauss Invests in Express Scripts Guru adds to holdings in State Street and Marathon Petroleum
Barrow, Hanley, Mewhinney & Strauss became the second-largest shareholder among the gurus with its first-quarter purchase of a 9,772,328-share stake in Express Scripts Holding Co. (NASDAQ:ESRX), a St. Louis-based pharmacy benefit management services provider. Read more...
Pioneer Sells Most of Stakes in Bank of America, Express Scripts, Citizens Financial Guru raises positions in Goldman Sachs, Home Depot, Chevron
Pioneer Investments (Trades, Portfolio)’ preferred sectors are Technology and Healthcare, but its most prominent transactions in the first quarter covered a wide range of sectors. Read more...
The PBM Empire Strikes Back Some of the largest pharmacy benefit managers are driving significant change in drug pricing
I had the privilege of speaking at the GuruFocus Conference in Omaha. The basis of my talk was finding value in health care. Read more...
Wallace Weitz Comments on Express Scripts Guru stock highlight
Express Scripts (NASDAQ:ESRX) is the largest stand-alone pharmacy benefits manager (PBM) in the United States, helping health benefit providers improve access to (and the affordability of) prescription drugs. Negotiations with Anthem, Express Scripts’ largest customer, hit an impasse early in the quarter. Anthem elected to bring the details of the disagreement public at a widely attended industry conference in January, providing the investment community a lens into how far the two companies were apart on the economics of their existing contract. Since then, Anthem has also filed a lawsuit against Express Scripts. While we hope a mutually agreeable solution will eventually be achieved, it remains possible (some believe likely) that Anthem will choose not to renew its contract with Express in 2019. We have run scenarios encompassing a range of different outcomes, and we believe Express Scripts’ shares are undervalued in all but the most dire. We continue to monitor contract-related developments and are otherwise heartened by improved execution across the other 84% of Express Scripts’ enterprise. Read more...
First Pacific Advisors Slashes Stake in CVS Health Guru nearly triples stake in United Technologies, invests in stake in Esterline Technologies
First Pacific Advisors (Trades, Portfolio), a Los Angeles-based investment management firm, has a preference for stocks in the technology and financial services sectors, but its most eye-popping deal in the third quarter was the reduction of a stake in the health care sector. Read more...
Health Care Stocks Play Prominent Roles in Steven Romick's Transactions Guru reduces stakes in CVS Health, Express Scripts, Thermo Fisher in 3rd quarter
The health care sector occupies a low position in Steven Romick (Trades, Portfolio)’s sector weightings, but those companies were among his most prominent third-quarter trades. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 17.66
ESRX's P/E(ttm) is ranked higher than
55% of the 22 Companies
in the Global Health Care Plans industry.

( Industry Median: 20.72 vs. ESRX: 17.66 )
Ranked among companies with meaningful P/E(ttm) only.
ESRX' s P/E(ttm) Range Over the Past 10 Years
Min: 13.51  Med: 26.72 Max: 36.23
Current: 17.66
13.51
36.23
Forward P/E 10.53
ESRX's Forward P/E is ranked higher than
83% of the 12 Companies
in the Global Health Care Plans industry.

( Industry Median: 14.10 vs. ESRX: 10.53 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 17.66
ESRX's PE(NRI) is ranked higher than
61% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 21.67 vs. ESRX: 17.66 )
Ranked among companies with meaningful PE(NRI) only.
ESRX' s PE(NRI) Range Over the Past 10 Years
Min: 13.38  Med: 26.37 Max: 35.5
Current: 17.66
13.38
35.5
Price/Owner Earnings (ttm) 10.23
ESRX's Price/Owner Earnings (ttm) is ranked higher than
80% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 14.33 vs. ESRX: 10.23 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ESRX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 8.8  Med: 15.54 Max: 28.55
Current: 10.23
8.8
28.55
P/B 2.92
ESRX's P/B is ranked lower than
72% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 2.53 vs. ESRX: 2.92 )
Ranked among companies with meaningful P/B only.
ESRX' s P/B Range Over the Past 10 Years
Min: 1.85  Med: 7.34 Max: 31.78
Current: 2.92
1.85
31.78
P/S 0.47
ESRX's P/S is ranked higher than
50% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.46 vs. ESRX: 0.47 )
Ranked among companies with meaningful P/S only.
ESRX' s P/S Range Over the Past 10 Years
Min: 0.41  Med: 0.63 Max: 1.08
Current: 0.47
0.41
1.08
PFCF 10.77
ESRX's PFCF is ranked higher than
62% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.71 vs. ESRX: 10.77 )
Ranked among companies with meaningful PFCF only.
ESRX' s PFCF Range Over the Past 10 Years
Min: 8.32  Med: 14.92 Max: 26.08
Current: 10.77
8.32
26.08
POCF 9.99
ESRX's POCF is ranked higher than
71% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.23 vs. ESRX: 9.99 )
Ranked among companies with meaningful POCF only.
ESRX' s POCF Range Over the Past 10 Years
Min: 8.05  Med: 13.62 Max: 23.73
Current: 9.99
8.05
23.73
EV-to-EBIT 12.94
ESRX's EV-to-EBIT is ranked higher than
55% of the 22 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.22 vs. ESRX: 12.94 )
Ranked among companies with meaningful EV-to-EBIT only.
ESRX' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.8  Med: 16.7 Max: 30.2
Current: 12.94
8.8
30.2
EV-to-EBITDA 8.64
ESRX's EV-to-EBITDA is ranked higher than
59% of the 22 Companies
in the Global Health Care Plans industry.

( Industry Median: 8.98 vs. ESRX: 8.64 )
Ranked among companies with meaningful EV-to-EBITDA only.
ESRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.2  Med: 12.5 Max: 22.4
Current: 8.64
8.2
22.4
PEG 1.04
ESRX's PEG is ranked higher than
86% of the 14 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.41 vs. ESRX: 1.04 )
Ranked among companies with meaningful PEG only.
ESRX' s PEG Range Over the Past 10 Years
Min: 0.43  Med: 1.09 Max: 1.7
Current: 1.04
0.43
1.7
Shiller P/E 31.18
ESRX's Shiller P/E is ranked lower than
69% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 28.53 vs. ESRX: 31.18 )
Ranked among companies with meaningful Shiller P/E only.
ESRX' s Shiller P/E Range Over the Past 10 Years
Min: 30.66  Med: 46.59 Max: 80.67
Current: 31.18
30.66
80.67
Current Ratio 0.55
ESRX's Current Ratio is ranked lower than
95% of the 22 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.11 vs. ESRX: 0.55 )
Ranked among companies with meaningful Current Ratio only.
ESRX' s Current Ratio Range Over the Past 10 Years
Min: 0.55  Med: 0.85 Max: 2.21
Current: 0.55
0.55
2.21
Quick Ratio 0.47
ESRX's Quick Ratio is ranked lower than
91% of the 22 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.08 vs. ESRX: 0.47 )
Ranked among companies with meaningful Quick Ratio only.
ESRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.47  Med: 0.76 Max: 2.15
Current: 0.47
0.47
2.15
Days Inventory 6.95
ESRX's Days Inventory is ranked lower than
56% of the 9 Companies
in the Global Health Care Plans industry.

( Industry Median: 5.05 vs. ESRX: 6.95 )
Ranked among companies with meaningful Days Inventory only.
ESRX' s Days Inventory Range Over the Past 10 Years
Min: 3.02  Med: 4.25 Max: 8.09
Current: 6.95
3.02
8.09
Days Sales Outstanding 26.54
ESRX's Days Sales Outstanding is ranked higher than
63% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 30.63 vs. ESRX: 26.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
ESRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 13.97  Med: 21.38 Max: 37.15
Current: 26.54
13.97
37.15
Days Payable 16.48
ESRX's Days Payable is ranked lower than
93% of the 14 Companies
in the Global Health Care Plans industry.

( Industry Median: 55.99 vs. ESRX: 16.48 )
Ranked among companies with meaningful Days Payable only.
ESRX' s Days Payable Range Over the Past 10 Years
Min: 5.7  Med: 11.5 Max: 13.5
Current: 16.48
5.7
13.5

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 6.10
ESRX's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.20 vs. ESRX: 6.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ESRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.4  Med: 0 Max: 6.1
Current: 6.1
-14.4
6.1

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.70
ESRX's Price/Projected FCF is ranked higher than
81% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.06 vs. ESRX: 0.70 )
Ranked among companies with meaningful Price/Projected FCF only.
ESRX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.68  Med: 1.41 Max: 62.6
Current: 0.7
0.68
62.6
Price/DCF (Earnings Based) 0.84
ESRX's Price/DCF (Earnings Based) is ranked higher than
89% of the 9 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.16 vs. ESRX: 0.84 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.74
ESRX's Price/Median PS Value is ranked higher than
77% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.00 vs. ESRX: 0.74 )
Ranked among companies with meaningful Price/Median PS Value only.
ESRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.5  Med: 0.93 Max: 1.69
Current: 0.74
0.5
1.69
Price/Peter Lynch Fair Value 1.09
ESRX's Price/Peter Lynch Fair Value is ranked higher than
69% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.15 vs. ESRX: 1.09 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ESRX' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.42  Med: 1.1 Max: 2.44
Current: 1.09
0.42
2.44
Earnings Yield (Greenblatt) (%) 7.70
ESRX's Earnings Yield (Greenblatt) (%) is ranked higher than
62% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 7.30 vs. ESRX: 7.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ESRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.3  Med: 6 Max: 11.3
Current: 7.7
3.3
11.3
Forward Rate of Return (Yacktman) (%) 23.88
ESRX's Forward Rate of Return (Yacktman) (%) is ranked higher than
76% of the 17 Companies
in the Global Health Care Plans industry.

( Industry Median: 18.71 vs. ESRX: 23.88 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ESRX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 22.2  Med: 29.7 Max: 37.4
Current: 23.88
22.2
37.4

More Statistics

Revenue (TTM) (Mil) $101,412
EPS (TTM) $ 4.04
Beta0.84
Short Percentage of Float3.91%
52-Week Range $65.55 - 89.20
Shares Outstanding (Mil)630.22

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 102,611 106,034 112,156
EPS ($) 6.35 6.82 7.85
EPS w/o NRI ($) 6.35 6.82 7.85
EPS Growth Rate
(3Y to 5Y Estimate)
26.40%
Dividends Per Share ($)
» More Articles for ESRX

Headlines

Articles On GuruFocus.com
Growth at a Reasonable Price Sep 15 2016 
15 Questions With Brian Grosso Sep 14 2016 
Healthcare Growth Stocks in the S&P 500: Part 2 Aug 12 2016 
Healthcare Growth Stocks in the S&P 500: Part 2 Aug 12 2016 
Arnold Van Den Berg 2nd Quarter: Cuts Back on Gold Miners, Gets More Bullish on Oil Jul 25 2016 
Van Den Berg Made 6 New Buys in 2nd Quarter Jul 24 2016 
David Rolfe Comments on Express Scripts Jul 13 2016 
David Rolfe's Wedgewood Partners 2nd Quarter 2016 Client Letter Jul 12 2016 
David Rolfe Nearly Divests Stake in M&T Bank Jun 26 2016 
Brandes Investments Comments on Express Scripts Jun 15 2016 

More From Other Websites
Express Scripts Launches Inflammatory Conditions Care Value Program(SM), Making America's Costliest... Sep 17 2016
Express Scripts Launches Diabetes Care Value Program℠, Guaranteeing More Affordable,... Sep 17 2016
Express Scripts Holding Company to Present at an Upcoming Conference Sep 17 2016
Growth at a Reasonable Price Sep 15 2016
These 3 Healthcare Stocks Will Give You Growth in This Slow Economy Sep 15 2016
Advance Has Run Its Course for Express Scripts Sep 12 2016
These companies you've never heard of are about to incite another massive drug price outrage Sep 12 2016
Companies you've never heard of are making a killing off high drug prices Sep 10 2016
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Express Scripts Holding Company... Sep 09 2016
Express Scripts tries to rein in pricey inflammatory drugs Sep 08 2016
Express Scripts Launches Inflammatory Conditions Care Value Program(SM), Making America's Costliest... Sep 08 2016
Express Scripts Launches Inflammatory Conditions Care Value Program(SM), Making America's Costliest... Sep 08 2016
Looking for Bargains? Check Out High-Quality Healthcare Stocks Sep 07 2016
Express Scripts: Part of the Drug Price Solution or Part of the Problem? Sep 02 2016
Express Scripts Holding Company to Present at an Upcoming Conference Sep 01 2016
Express Scripts Holding Company to Present at an Upcoming Conference Sep 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)